Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.

Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH.

Contemp Clin Trials. 2018 May;68:7-13. doi: 10.1016/j.cct.2018.03.001. Epub 2018 Mar 10.

PMID:
29535047
2.

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.

Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J.

Target Oncol. 2017 Dec;12(6):775-785. doi: 10.1007/s11523-017-0530-5.

3.

Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.

Cives M, Soares HP, Strosberg J.

Curr Opin Oncol. 2016 Jul;28(4):359-66. doi: 10.1097/CCO.0000000000000299. Review.

PMID:
27138571
4.

Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.

Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR.

Cancer Chemother Pharmacol. 2015 Jul;76(1):61-7. doi: 10.1007/s00280-015-2744-5. Epub 2015 May 13.

PMID:
25969130
5.

Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.

Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E.

Mol Cancer Ther. 2015 Apr;14(4):1014-23. doi: 10.1158/1535-7163.MCT-14-0669. Epub 2015 Feb 11.

6.

Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.

Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt E.

PLoS One. 2014 Dec 10;9(12):e114573. doi: 10.1371/journal.pone.0114573. eCollection 2014.

7.

Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.

Rozengurt E, Soares HP, Sinnet-Smith J.

Mol Cancer Ther. 2014 Nov;13(11):2477-88. doi: 10.1158/1535-7163.MCT-14-0330. Epub 2014 Oct 16. Review.

8.

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.

Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM.

Cancer Chemother Pharmacol. 2014 Apr;73(4):839-45. doi: 10.1007/s00280-014-2414-z. Epub 2014 Feb 23.

PMID:
24562589
9.

Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.

Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E.

PLoS One. 2013;8(2):e57289. doi: 10.1371/journal.pone.0057289. Epub 2013 Feb 21.

10.

New treatments compared to established treatments in randomized trials.

Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I.

Cochrane Database Syst Rev. 2012 Oct 17;10:MR000024. doi: 10.1002/14651858.MR000024.pub3.

11.

Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols.

Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A.

J Clin Epidemiol. 2012 Jun;65(6):602-9. doi: 10.1016/j.jclinepi.2011.10.016. Epub 2012 Mar 16. Review.

12.

Velimogene aliplasmid.

Soares HP, Lutzky J.

Expert Opin Biol Ther. 2010 May;10(5):841-51. doi: 10.1517/14712598.2010.481280. Review.

PMID:
20367461
13.

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.

Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH; STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T.

JAMA. 2010 Mar 24;303(12):1180-7. doi: 10.1001/jama.2010.310. Review.

PMID:
20332404
14.

Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2).

Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schünemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH.

Trials. 2009 Jul 6;10:49. doi: 10.1186/1745-6215-10-49.

15.

Burnout in cancer professionals: a systematic review and meta-analysis.

Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abrão MN, Diniz RW, Miranda Vda C, Soares HP, Del Giglio A.

Eur J Cancer Care (Engl). 2008 Nov;17(6):524-31. doi: 10.1111/j.1365-2354.2008.00927.x. Epub 2008 Sep 1. Review.

PMID:
18771533
16.

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006.

Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL.

Arch Intern Med. 2008 Mar 24;168(6):632-42. doi: 10.1001/archinte.168.6.632.

17.

Recommendations on the use of 18F-FDG PET in oncology.

Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF.

J Nucl Med. 2008 Mar;49(3):480-508. doi: 10.2967/jnumed.107.047787. Epub 2008 Feb 20.

18.

A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer.

Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G.

J Thorac Oncol. 2007 Dec;2(12):1091-7. Review.

19.

EGFR targeting of solid tumors.

Rocha-Lima CM, Soares HP, Raez LE, Singal R.

Cancer Control. 2007 Jul;14(3):295-304. Review.

PMID:
17615536
20.

Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups.

Kumar A, Soares HP, Balducci L, Djulbegovic B; National Cancer Institute.

J Clin Oncol. 2007 Apr 1;25(10):1272-6. Review.

PMID:
17401017
21.

Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design.

Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B.

Cancer Control. 2007 Apr;14(2):160-6. Review.

PMID:
17387301
22.

Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence.

Soares HP, Kumar A, Djulbegovic B.

Cancer Treat Rev. 2007 Feb;33(1):87-9. Epub 2006 Nov 1. No abstract available.

PMID:
17081695
23.

Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence.

Soares HP, Kumar A, Djulbegovic B.

Cancer Treat Rev. 2006 Dec;32(8):652-5. Epub 2006 Sep 27. No abstract available.

PMID:
17008011
24.

Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence.

Kumar A, Soares HP, Djulbegovic B.

Cancer Treat Rev. 2006 Nov;32(7):577-80. Epub 2006 Aug 21. No abstract available.

PMID:
16919883
25.

What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms.

Djulbegovic B, Soares HP, Kumar A.

Cancer Treat Rev. 2006 Nov;32(7):572-6. Epub 2006 Aug 17. No abstract available.

PMID:
16914268
26.

Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma.

Kumar A, Soares HP.

Cancer Treat Rev. 2006 Oct;32(6):487-90. Epub 2006 May 24. No abstract available.

PMID:
16725265
27.

Evaluation of new treatments in radiation oncology: are they better than standard treatments?

Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B.

JAMA. 2005 Feb 23;293(8):970-8.

28.

Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis.

Weinschenker P, Soares HP, Clark O, Del Giglio A.

Breast Cancer Res Treat. 2004 Oct;87(3):215-24.

PMID:
15528964
29.

Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients.

Samano ES, Goldenstein PT, Ribeiro Lde M, Lewin F, Filho ES, Soares HP, del Giglio A.

Sao Paulo Med J. 2004 Mar 4;122(2):60-3. Epub 2004 Jul 5.

30.

Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer.

Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, de Santana TL, Pinto FN, del Giglio A.

Am J Clin Oncol. 2004 Jun;27(3):304-6.

PMID:
15170153
31.

Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group.

Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B; Radiation Therapy Oncology Group.

BMJ. 2004 Jan 3;328(7430):22-4.

32.

Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy.

Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio A.

Clin Breast Cancer. 2002 Aug;3(3):201-5.

PMID:
12196278
33.

Detection of Helicobacter pylori in gastric cancer.

Pereira LP, Waisberg J, André EA, Zanoto A, Mendes Júnior JP, Soares HP.

Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6.

PMID:
12068534
34.

CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy.

Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V, Giralt S, del Giglio A.

Breast Cancer Res Treat. 2001 Apr;66(3):249-54.

PMID:
11510696
35.

Supplemental Content

Loading ...
Support Center